Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1999 Giugno;43(2) > The Quarterly Journal of Nuclear Medicine 1999 Giugno;43(2):119-24

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 1999 Giugno;43(2):119-24

RADIOPHARMACOLOGY 

Polypeptides ­from ­phage dis­play. A super­i­or ­source of in ­vivo imag­ing ­agents

Ladner R. C.

From the Dyax Corp., Therapeutic and Diagnostic Division Cambridge, Massachusetts, USA

To ­decide wheth­er expe­ri­ence teach­es ­that ­small pro­teins and con­strained pep­tides hav­ing ­high affin­ity for molec­u­lar tar­gets can be engi­neered to ­have suit­able phar­ma­cok­i­net­ics for imag­ing. Phage dis­play, a molec­u­lar diver­sity tech­nol­o­gy, ­allows selec­tion of poly­pep­tides hav­ing ­high affin­ity and spec­i­fic­ity for ­almost any tar­get. These poly­pep­tides can be mod­i­fied in ­ways ­that ­improve phar­ma­cok­i­net­ics ­with accept­able ­impact on bind­ing. Often, rel­a­tive­ly few chang­es con­fers phar­ma­cok­i­net­ics suit­able for imag­ing on poly­pep­tides select­ed for affin­ity and spec­i­fic­ity to a tar­get and for stabil­ity. It is like­ly ­that few var­i­ants of ­phage-select­ed pro­teins and con­strained pep­tides ­will ­need to be test­ed to ­obtain a use­ful imag­ing ­agent.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina